26
February 2024
Oncimmune Holdings
plc
("Oncimmune" or the "Company")
Results
of Annual General Meeting
Oncimmune Holdings plc (AIM: ONC.L),
a leading autoantibody profiling company to the pharmaceutical and
biotechnology industry, announces that at the Company's Annual
General Meeting held earlier today all resolutions were duly
passed.
The Notice of Annual General Meeting
containing the full text of all of the resolutions is available on
the Company's website at www.oncimmune.com,
the results of the proxy vote on each of the resolutions will also
be made available on the Company's website
shortly.
The Company will be holding a
general meeting to, amongst other things, receive the Company's
annual report for year ended 31 August 2023 ("FY23") and to approve
the report on Directors' remuneration for FY23.
A further announcement setting out
details of this general meeting will be made in due
course.
Oncimmune
Holdings plc
contact@oncimmune.com
Singer Capital Markets (Nominated
Adviser and Broker)
Philip Davies, Harry Gooden, James
Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan
Bate
+44 (0)20 3829 5000
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a precision medicine
company, specialising in analysing immune interactions through the
autoantibody profile. Taking a platform approach to generating
insights, Oncimmune is partnering with global pharmaceutical and
biotech companies, as well as contract research organisations
(CROs) to discover novel biomarkers for the development of more
targeted and effective therapies across many immune-mediated
diseases. Our mission at Oncimmune is to enable precision medicine.
We help our partners to discover novel biomarkers, drug targets and
predict treatment efficacy through the application of our platform.
We are able to do this by deploying our world class scientific team
and our cutting-edge technology platform, built on years of
experience in the field. Our aim is to make this an essential tool
in drug discovery and development.
Oncimmune is headquartered in the
UK, with its discovery and development facility based in Dortmund,
Germany and a business development team based in the US and
Europe.
For more information,
visit www.oncimmune.com